Cogent Biosciences Inc (COGT)

NASD · Healthcare · Biotechnology · USA

Cogent Biosciences Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Intrinsic value, DCF valuation, financial health and value investing analysis for the Cogent Biosciences Inc stock.

Our verdict on COGT

Not valued: We cannot value this company yet.

ETFs with the most weight in COGT

F/m Emerald Life Sciences Innovation ETF (LFSC): 7.5% of the fund
Fidelity Disruptive Medicine ETF (FMED): 2.9% of the fund
Invesco Dorsey Wright SmallCap Momentum ETF (DWAS): 0.6% of the fund

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Biotechnology

All 596 Biotechnology stocks

Cheaper than COGT in Biotechnology

Lakefront Biotherapeutics NV ADR (LKFT): undervalued, 79% margin of safety
Arbutus Biopharma Corp (ABUS): undervalued, 79% margin of safety
MeiraGTx Holdings plc (MGTX): undervalued, 73% margin of safety
Bicycle Therapeutics Plc ADR (BCYC): undervalued, 72% margin of safety
Innoviva Inc (INVA): undervalued, 71% margin of safety
CorMedix Inc (CRMD): undervalued, 66% margin of safety

135 more in this industry show a wider margin of safety.

Is COGT undervalued or overvalued?

We do not publish a verdict on COGT yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of COGT?

We do not publish one (as of the 2026-10-19 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.